|
gptkbp:instanceOf
|
erythropoiesis-stimulating agent
biopharmaceutical drug
|
|
gptkbp:administeredBy
|
injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2001
|
|
gptkbp:ATCCode
|
gptkb:B03XA02
|
|
gptkbp:brand
|
gptkb:Aranesp
|
|
gptkbp:CASNumber
|
gptkb:208734-13-2
|
|
gptkbp:contraindication
|
uncontrolled hypertension
|
|
gptkbp:developedBy
|
gptkb:Amgen
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
darbepoetin alfa
|
|
gptkbp:indication
|
treatment of anemia in adult cancer patients receiving chemotherapy
treatment of symptomatic anemia in adults and children with chronic renal failure
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:protein
|
|
gptkbp:marketedAs
|
gptkb:Amgen
|
|
gptkbp:mechanismOfAction
|
stimulates erythropoiesis
|
|
gptkbp:proteinSequence
|
recombinant DNA technology
|
|
gptkbp:relatedTo
|
gptkb:erythropoietin
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
edema
hypertension
thromboembolic events
|
|
gptkbp:UNII
|
QXW8YN15FJ
|
|
gptkbp:usedFor
|
gptkb:anemia
anemia due to chronic kidney disease
anemia due to chemotherapy
|
|
gptkbp:bfsParent
|
gptkb:Erythropoietin
gptkb:erythropoietin
|
|
gptkbp:bfsLayer
|
6
|